171 related articles for article (PubMed ID: 14754435)
1. Fitness variations and their impact on the evolution of antiretroviral drug resistance.
Menéndez-Arias L; Martínez MA; Quiñones-Mateu ME; Martinez-Picado J
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):355-71. PubMed ID: 14754435
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
3. The HIV-1 Reverse Transcriptase A62V Mutation Influences Replication Fidelity and Viral Fitness in the Context of Multi-Drug-Resistant Mutations.
Maldonado JO; Mansky LM
Viruses; 2018 Jul; 10(7):. PubMed ID: 30029500
[TBL] [Abstract][Full Text] [Related]
4. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness.
Berkhout B
J Biomed Sci; 1999; 6(5):298-305. PubMed ID: 10494036
[TBL] [Abstract][Full Text] [Related]
6. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
[TBL] [Abstract][Full Text] [Related]
7. Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.
Wang D; Hicks CB; Goswami ND; Tafoya E; Ribeiro RM; Cai F; Perelson AS; Gao F
J Virol; 2011 Jul; 85(13):6403-15. PubMed ID: 21490094
[TBL] [Abstract][Full Text] [Related]
8. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.
Brenner BG; Routy JP; Petrella M; Moisi D; Oliveira M; Detorio M; Spira B; Essabag V; Conway B; Lalonde R; Sekaly RP; Wainberg MA
J Virol; 2002 Feb; 76(4):1753-61. PubMed ID: 11799170
[TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
10. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
[TBL] [Abstract][Full Text] [Related]
11. A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapy.
Weber J; Rangel HR; Chakraborty B; Tadele M; Martinez MA; Martinez-Picado J; Marotta ML; Mirza M; Ruiz L; Clotet B; Wrin T; Petropoulos CJ; Quiñones-Mateu ME
J Gen Virol; 2003 Aug; 84(Pt 8):2217-2228. PubMed ID: 12867654
[TBL] [Abstract][Full Text] [Related]
12. HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.
Prado JG; Parkin NT; Clotet B; Ruiz L; Martinez-Picado J
Clin Infect Dis; 2005 Sep; 41(5):729-37. PubMed ID: 16080097
[TBL] [Abstract][Full Text] [Related]
13. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
14. Implications of antiretroviral resistance on viral fitness.
Nijhuis M; Deeks S; Boucher C
Curr Opin Infect Dis; 2001 Feb; 14(1):23-8. PubMed ID: 11979111
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of HIV antiretroviral drugs progress toward drug resistance.
Ammaranond P; Sanguansittianan S
Fundam Clin Pharmacol; 2012 Feb; 26(1):146-61. PubMed ID: 22118474
[TBL] [Abstract][Full Text] [Related]
16. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
17. Novel drug resistance mutations in HIV: recognition and clinical relevance.
Perno CF; Svicher V; Ceccherini-Silberstein F
AIDS Rev; 2006; 8(4):179-90. PubMed ID: 17219733
[TBL] [Abstract][Full Text] [Related]
18. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy.
Nijhuis M; Schuurman R; de Jong D; Erickson J; Gustchina E; Albert J; Schipper P; Gulnik S; Boucher CA
AIDS; 1999 Dec; 13(17):2349-59. PubMed ID: 10597776
[TBL] [Abstract][Full Text] [Related]
19. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
20. Combined antiretroviral therapy and immune pressure lead to in vivo HIV-1 recombination with ancestral viral genomes.
Buzón MJ; Wrin T; Codoñer FM; Dalmau J; Phung P; Bonjoch A; Coakley E; Clotet B; Martinez-Picado J
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):109-17. PubMed ID: 21372727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
